Mass Drug-Vaccine combo takes on malaria in 10,000-Person trial

NCT ID NCT06068530

Prevention Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether giving entire communities antimalarial drugs along with a malaria vaccine can reduce the spread of the disease better than drugs alone, vaccine alone, or no extra intervention. About 10,000 people aged 6 months and older in malaria-prone villages will take part. The goal is to see if this combined approach lowers malaria cases and infections over two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Dihydroartemisinin/piperaquine and single low-dose primaquine (antimalarial drugs) plus R21/Matrix-M malaria vaccine
What this could lead to: If successful, this could show that combining mass drug administration with vaccination is a powerful way to reduce malaria transmission and save lives.
What could go wrong: This is a large trial, but results may vary by region and the approach may be logistically challenging. There are also risks of side effects from the drugs or vaccine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Current residence in a study village irrespective of permanence * Age 6 months and above (no upper age limit) * Written informed consent provided by participants (or a parent/guardian in case the participant is under 18 years old) Exclusion Criteria: * Pregnancy, plan to get pregnant, or breastfeeding. * Acute illness requiring intervention * A history of an adverse reaction to study drugs/vaccine and prior receipt of any other malaria vaccine or enrolment in another intervention trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plasmodium falciparum malaria are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plasmodium falciparum malaria

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

2 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Mass Drug-Vaccine combo takes on malaria in 10,000-Person trial

What the study statuses mean